<DOC>
	<DOCNO>NCT02850081</DOCNO>
	<brief_summary>The investigator hypothesize pre-operative statin use neuroprotective maximal dos . The goal determine safety , feasibility , efficacy maximize statin dos two week ( 12-18 day ) prior CEA use change performance battery neuropsychometric test outcome measure . Study recruit patient base preexist statin regimen . The investigator hypothesize asymptomatic CEA patient : 1 ) Pre-operative statin use neuroprotective early cognitive dysfunction ( eCD ) lower risk early mortality . 2 ) Maximal dos may essential achieve optimal neuroprotection eCD .</brief_summary>
	<brief_title>Statin Neuroprotection Carotid Endarterectomy : Safety , Feasibility Outcomes</brief_title>
	<detailed_description>Carotid endarterectomy ( CEA ) common surgery perform reduce risk stroke patient carotid artery narrow . Statins , class drug usually use low blood cholesterol , may protect brain surgery . Specific statin show protect brain surgery compare others . eCD affect 25 % patient undergoing CEA 15 % undergoing asymptomatic CEA . It associate marked elevation tissue marker cerebral injury associate earlier post-CEA mortality . This clinically significant , subtle , cerebral injury 10 time common stroke mechanism appear similarly relate regional hypoperfusion ischemia . It imperative determine prospective randomize trial whether alteration/increase preoperative statin regimens lead improved neurologic outcome even low incidence stroke possibly great survival . In order optimally design conduct trial critical : 1 ) explore safety feasibility alter statin regimen acutely ( approximately 2 week ) CEA , 2 ) clearly establish neuroprotective outcome acute alteration statin regimen . This would promote good understand statin neuroprotection human determine statin treatment affords neuroprotection patient undergo one commonly perform procedure US .</detailed_description>
	<mesh_term>Carotid Stenosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Age ≥ 18 year age . 2 . Patient currently atorvastatin simvastatin rosuvastatin statin naïve ( statin last 30 day ) . 3 . The patient unilateral bilateral carotid artery stenosis consider severe ( carotid artery diameter reduction ≥ 70 % ) define : 1 . Peak systolic velocity least 230 cm/s plus least one : 2 . End diastolic velocity ≥ 100 cm/s OR 3 . CTA show ≥ 70 % stenosis OR 4 . MRA show ≥ 70 % stenosis 4 . This stenosis cause stroke , transient cerebral ischemia , relevant neurological symptom past . 5 . The patient 's attend doctor ( ) ( PMD , cardiologist , vascular/neurosurgeon ) AND patient decide proceed CEA treat patient 's severe carotid stenosis . 6 . The patient know circumstance condition likely preclude 1 year followup adherence study protocol . 7 . The patient independent Activities Daily Living baseline . 8 . Patient ability provide inform consent . 1 . Patient underlying disease atherosclerosis ( i.e . autoimmune disease , know active malignancy ) . 2 . Patient document dementia screen base abnormal Baseline MoCA ( ≤25 ) AD8 ( ≥2 ) . 3 . Patient 's life expectancy &lt; 12 month . 4 . Patient advance renal failure ( serum creatinine &gt; 2.5 mg/dL ) 5 . Patient evidence severe congestive heart failure history endstage cardiovascular disease ( e.g . CHF NYHA Class III IV unstable angina ) . 6 . Patient history intolerance allergic reaction statin ( myotoxicity , hepatic dysfunction , rash , etc . ) 7 . Patient receive investigational drug within 30 day . 8 . Patient pregnant lactating . 9 . Patient currently take follow show interact atorvastatin and/or simvastatin and/or rosuvastatin ( per current drug package insert ) : Cyclosporine ; HIV Protease Inhibitors/Antivirals ( e.g . rotanavir plus rotanavir , tipranavir , lopinavir , boceprevir , saquinovir , darunavir , fosamprenavir , nelfinavir , efavirenz/tenofobir , atazanavir , simeprevir ) ; Hep C Protease Inhibitor/Antivirals ( e.g . telapravir ) ; Antibiotics ( i.e . cobicistatcontaining product like Tybost , rifampin/rifampicin , clarithromycin , telithromycin , erythromycin ) ; Antifungals ( i.e . itraconazole , ketoconazole , posaconazole , voriconazole , fluconazole ) ; *Gemfibrozil ; Other Fenofibrates ( e.g . Tricor , fibric acid ) ; Niacin &gt; 1g/day statin combination niacin ( e.g . Vytorin , Simcor ) ; Colchicine ; Danazol ; Calcium Channel Blockers : Diltiazem , Varapamil ; Dronedarone ; Amiodarone ; Digoxin ; Ranolazine ; Nefazodone ; Warfarin/Coumadin ; Lomitapide ; Grapefruit juice &gt; 1.2 liters/day ( 40.5 ounces/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Carotid endarterectomy</keyword>
	<keyword>CEA</keyword>
	<keyword>stroke</keyword>
	<keyword>asymptomatic stenosis</keyword>
</DOC>